The prevalence of anemia in inflammatory bowel disease (IBD) has been broadly described.
The recurrence, type and burden of anemia remain unenlightened.
Dr Palle Bager and colleagues from Denmark described this.
The secondary objective was to evaluate the implementation of European guidelines.
The team performed a longitudinal follow-up study including 300 IBD outpatients from 6 centers in Scandinavia.
Patients were enrolled in a research cohort, in which each center included 5% of their IBD cohort.
|Pure anemia of chronic disease was present in 21% of burden time|
|Scandanavian Journal of Gastroenterology|
The study was prospectively planned, while data were retrospectively collected.
The burden of anemia was calculated as number of months with anemia.
The European guidelines were used as the standard for anemia management.
The researchers found that anemia affected more than 50% of IBD outpatients during the 2-year observation period.
The team noted that 20% of the total observation time was spent in anemia.
Over the 7200 months of observation, anemia was found in 1410 months.
The research team observed that the most frequent type was combined anemia.
Combined anemia covers both anemia of chronic disease, and iron-deficiency anemia.
The team noted that pure anemia of chronic disease was present in 21% of burden time, while pure iron-deficiency anemia was present in 16% of burden time.
The European guidelines have mainly been implemented.
Dr Bager's team concludes, "Anemia affected a majority of the IBD outpatients."
"One in five months, the patients were anemic."
"Anemia related to inflammation dominated the different types of anemia."
"Pure iron-deficiency anemia was found in for 16%."